World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The

World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The

Worldwide cancer affects more than 10 million people each year. This number is expected to increase by 2.4% by 2020 to 14 million each year. Worldwide approximately 22 million people are living with cancer and nearly 7 million people die. The most common cancers affecting the world include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder.



This Kalorama Information report - The World Market for Cancer Therapeutics and Biotherapeutics - focuses on several segments for cancer treatment. The report covers both currently marketed and late stage development cancer products. Revenues for each current market segment were generated using dollar and unit sales for each product.

The following approaches to cancer therapeutics are covered in the report:

• Biotherapeutics
  • Monoclonal Antibodies
  • Interleukins/ Interferons
  • Kinases and Other Treatments
  
  
• Chemotherapy
  • Alkylating Agents
  • Antimetabolites
  • Cytotoxic Agents
  • Plant Derivatives
  
  
• Hormone Therapy
  • Corticosteroids
  • Hormone Antagonists/ Antagonists
  • Aromatase Inhibitors
  • SERMS
  
  

The report includes market share by type of cancer and market share by company for each of the three major segments. It also includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview, description of products on the market, list of products in late-stage development, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.

A Primary Research Effort


The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.
All market data pertains to the world market at the manufacturers’ level.


Coverage of the Most Recent Product and Trends


The base year for data was 2008. Historical data was provided for the years 2004 through 2007, with forecast data provided for 2009 through 2013. Compound annual growth rates (CAGRs) are provided for the 2004-2008, 2009-2013 and 2004-2013 periods for each industry segment covered. Competitive analysis is provided for the year 2008. The forecasted market analysis for 2009-2013 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends. Some of the trends that affected this market include the following:

• Insurance and Reimbursement
  
• Drug Costs
  
• Personalized Medicine
  
• Alliances, Acquisitions and Licensing Agreements
  
• Alcohol’s Affect on Cancer Incidence
  
• Healthy Lifestyles Continue to Show Promise for Cancer Prevention
  
• Marketing and Distribution Trends
  
• Geographical Trends
  
• Elderly Clinical Trial Involvement
  
• Late-Stage Drug Development Trends
  

Profiles of Twelve Key Competitors


As part of its comprehensive coverage, the following companies are profiled:

• AstraZeneca (coverage of Arimidex, Casodex, Faslodex, Zoladex, Iressa, Nolvadex and other products)


• Biogen IDEC (coverage of Rituxan and other products)


• Bristol-Myers Squibb (coverage of Erbitux, Taxol, Ixempra, Sprycel and other products)


• Eli Lilly (coverage of Alimta, Gemzar and other products)


• Genentech (coverage of Avastin, Herceptin, Rituxan )


• Johnson & Johnson (coverage of Doxil, Velcade, Leustatin)


• Merck & Company (coverage of Zolinza and other products)


• Novartis (coverage of Femara, Gleevec/Glivec, Tasigna, Sandostatin, Proleukin, Afinitor and other products)


• Pfizer (coverage of Camptosar and Sutent)


• Roche (coverage of Xeloda, Avastin, MabThera, Herceptin, Tarceva and pipeline drugs)


• Sanofi-Aventis (coverage of Taxotere, Eloxatine and others)


• Schering-Plough (coverage of Intron A, Timodar/Temodal, Caelyx/Doxil and pipeline plans)

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Size and Growth of the Market

Issues and Trends Affecting Market

Leading Competitors

CHAPTER TWO: INTRODUCTION

What is Cancer

Biochemistry of Cancer Cells

Carcinogen Metabolism

Causes of Cancer Growth

Environmental Factors, DNA, RNA

Cellular Oncogenes

Tumor Suppressor Genes

History and Growth of the Cancer Treatment Market

Growth of Cancer Development

Industry Structure

Product Segments and Technology

Chemotherapy: At a Glance

Hormone Therapy: At A Glance

Biotherapy: AT a Glance

Radiation Therapy: At a Glance

Demographics and Statistics

Global Cancer Statistics

Demographics

Aging Population

Life Expectancy and Cancer

Description of Cancers

Bladder Cancer

Breast Cancer

Cervical Cancer

Colorectal Cancer

Esophageal Cancer

Head and Neck

Kidney

Leukemia

Liver

Lung Cancer

Lymphoma

Melanoma

Multiple Myeloma

Neuroblastoma

Ovarian Cancer

Pancreas

Prostate Cancer

Stomach Cancer

CHAPTER THREE: CHEMOTHERAPY

Overview

Product Descriptions and Examples

Alkylating Agents

Antimetabolites

Cytotoxic Agents

Plant Derivatives

Market Size and Growth

Markets by Product Type

Markets by Geographical Segments

U.S. Market

European Market

Japan Market

ROW Market

Market Data by Indication

Competitive Analysis

CHAPTER FOUR: HORMONE THERAPY

Overview

Product Descriptions and Examples

Corticosteroids

Synthetic Corticosteroids

Hormone Agonists and Antagonists

Estrogens

Androgens

Antiestrogens

Antiandrogens

Gonadotropin-releasing Hormone Analogues

Aromatase Inhibitors

Selective Estrogen Receptor Modulators (SERMs)

Market Size and Growth

Markets by Product Type

Markets by Geographical Segments

U.S. Market

Europe Market

Japan Market

ROW Market

Market Data by Indication

Competitive Analysis

CHAPTER FIVE: BIOTHERAPEUTICS

Overview

Product Descriptions and Examples

Monoclonal Antibodies

Avastin (bevacizumab)

Campath (alemtuzumab)

Erbitux (cetuximab)

Herceptin (trastuzumab)

Mylotarg (gemtuzumab ozogamicin)

Panorex (edrecolomab)

Rituxan (rituximab)

Vectibix (panitumumab)

Interleukins/Interferons

Alferon-N

Infergen

Intron A

Proleukin

Roferon A

Other Biotherapy

Antisense Oligonucleotides

Apoptosis

Growth Factors

Methylation

P53

Ras Protein Drugs

Regulatory Enzymes

Proteasome Inhibitors

Radioimmunotherapy

Market Size and Growth

Markets by Product Type

Markets by Geographical Segments

U.S. Market

Europe Market

Japan Market

ROW Market

Market Data by Indication

Competitive Analysis

CHAPTER SIX: WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST

Overview

Total Market Size and Forecast

Competitive Landscape

CHAPTER SEVEN: ISSUES AND TRENDS AFFECTING THE CANCER MARKET

Introduction

Insurance and Reimbursement Issues

Cancer Drug Costs

Personalized Medicine

Targeted Cancer Therapy

Pharmacogenomics

Alliances Acquisitions and Licensing Agreements

Patient-Reported Outcomes

Alcohol’s Affect on Cancer Incidence

Healthy Lifestyles Continue to Show Promise for Cancer Prevention

Possibility for a Healthier U.S. Population

Cancer Trends

Marketing and Distribution Trends

Geographical Trends

United States

Europe

Japan

Elderly Clinical Trial Involvement

Late-Stage Drug Development Trends

CHAPTER EIGHT: CORPORATE PROFILES

Introduction

AstraZeneca plc

Biogen IDEC, Inc.

Bristol-Myers Squibb Company

Eli Lilly & Company

Genentech, Inc.

Johnson & Johnson

Merck & Company, Inc.

Novartis AG

Pfizer, Inc.

Roche

Sanofi-Aventis

Schering-Plough Corporation

CHAPTER NINE: COMPANY DIRECTORY

LIST OF EXHIBITS

EXECUTIVE SUMMARY

Table 1-1 World Cancer Treatment Market, 2004-2013

Figure 1-1 World Cancer Treatment Market, 2004-2013

INTRODUCTION

Table 2-1 Viruses Associated with Cancer in Humans

Table 2-2 Cancer Therapy Approvals per Year in the United States, 1970-2008

Figure 2-1 Cancer Therapy Approvals per Year in the United States, 1970-2008

Table 2-3 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020

Figure 2-2 Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020

Table 2-4 Cancer Incidence and Mortality by Country 2007

Figure 2-3 Cancer Incidence by Country 2007

Figure 2-4 Cancer Deaths by Country 2007

Table 2-5 Total Cancer Incidence by Sex and Country, 2007

Figure 2-5 Total Cancer Incidence by Sex and Country, 2007

Table 2-6 World Population by Selected Geographical Region, 2007 - 2050

Figure 2-6 World Population by Selected Geographical Region, 2007-2050

Table 2-7 Estimated World Population by Age and Geographical Region, 2007

Figure 2-7 Estimated World Population by Age and Geographical Region, 2007

Table 2-8 Percent Population Over 65 by Year and Region

Figure 2-8 Estimated World Population by Age, 2007 and 2050

Table 2-9 Average Life Expectancy in Years by Country 1980 and 2008

Figure 2-9 Average Life Expectancy in Years by Country 1980 and 2008

Table 2-10 United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004

Table 2-11 United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004

Figure 2-12 Approved Cancer Therapies in the United States by Indication

Table 2-10 Types Of Leukemia

Table 2-11 Types Of Primary Lung Cancer

Table 2-12 Classification Of Non-hodgkin’s Lymphomas

Table 2-13 Malignant Conditions Of The Skin

CHEMOTHERAPY

Table 3-1 Leading Products, 2008

Table 3-2 Newly Approved Chemotherapy Agents and Newly Approved Indications, 2007 through 2009

Table 3-3 World Chemotherapy Market, 2004-2013

Figure 3-1 World Chemotherapy Market, 2004-2013

Table 3-4 World Chemotherapy Market, Market by Product Classification, 2004-2013

Figure 3-2 World Chemotherapy Market

Figure 3-3 World Chemotherapy Market

Figure 3-4 World Chemotherapy Market

Figure 3-5 World Chemotherapy Market

Figure 3-6 World Chemotherapy Market

Figure 3-7 World Chemotherapy Market

Table 3-5 World Chemotherapy Market

Figure 3-8 World Chemotherapy Market

Table 3-6 World Chemotherapy Market, Leading Suppliers Shares by Market Revenues, 2008

Figure 3-9 World Chemotherapy Market, Leading Suppliers Market Share, 2008

HORMONE THERAPY

Table 4-1 Leading Products, 2008

Table 4-2 Newly Approved Hormone Cancer Therapies and Additional Indications 2007 through 2009

Table 4-3 World Hormone Therapy Market, 2004-2013

Figure 4-1 World Hormone Therapy Market, 2004-2013

Table 4-4 World Hormone Therapy Market, Market by Product Classification, 2004-2013

Figure 4-2 World Hormone Therapy Market, Market by Product Classification Revenues, 2004-2013

Figure 4-3 World Hormone Therapy Market, Market by Product Classification and Percent Distribution, 2004-2013

Figure 4-4 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2008

Figure 4-5 World Hormone Therapy Market, Market by Product Classification and Percent Market Share, 2013

Figure 4-5 World Hormone Therapy Market

Figure 4-6 World Hormone Therapy Market

Table 4-6 World Hormone Therapy Market

Figure 4-7 World Hormone Therapy Market

Table 4-7 World Hormone Therapy Market, Leading Suppliers Shares by Market Revenues, 2008

Figure 4-8 World Hormone Therapy Market, Leading Suppliers Market Share, 2008

BIOTHERAPEUTICS

Table 5-1 Leading Products, 2008

Table 5-2 Newly Approved Biological Therapies and Additional Indications, 2007 through March 2009

Table 5-3 World Cancer Biotherapeutics Market, 2004-2013

Figure 5-1 World Cancer Biotherapeutics Market, 2004-2013

Table 5-4 World Cancer Biotherapeutics Market Market by Product Type, (Monoclonal Antibodies,
Interleukins/ Interferons,
Other) 2004-2013

Figure 5-2 World Cancer Biotherapeutics Market, Market by Product Classification (Monoclonal Antibodies,
Interleukins/ Interferons, Other)
OtherRevenues, 2004-2013

Figure 5-3 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Distribution, 2004-2013

Figure 5-4 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2008

Figure 5-5 World Cancer Biotherapeutics Market, Market by Product Classification and Percent Market Share, 2013

Figure 5-6 World Cancer Biotherapeutics Market

Figure 5-7 World Cancer Biotherapeutics Market

Table 5-5 World Cancer Biotherapeutics Market

Figure 5-8 World Cancer Biotherapeutics Market

Table 5-6 World Biotherapeutics Market, Leading Suppliers Shares by Market Revenues, 2008

Figure 5-9 World Cancer Biotherapeutics Market, Leading Suppliers Market Share, 2008

WORLD CANCER THERAPIES: TOTAL MARKET SIZE AND FORECAST

Table 6-1 World Cancer Market Market by Product Type, 2004-2013

Figure 6-1 World Cancer Market, Market by Product Type Revenues, 2004-2013

Figure 6-2 World Cancer Market, Market by Product Type and Percent Distribution, 2004-2013

Figure 6-3 World Cancer Market, Market by Product Type and Percent Market Share, 2008

Figure 6-4 World Cancer Market, Market by Product Type and Percent Market Share, 2013

Table 6-2 World Cancer Market, Top Five Suppliers Shares by Market Revenues, 2008

Figure 6-5 World Cancer Market, Top Five Suppliers Market Share, 2008 Issues and Trends Affecting the Cancer Market

ISSUES AND TRENDS AFFECTING THE CANCER MARKET

Table 7-1 Obesity Rates by State

Table 7-2 Select Products in Development by Product Name

Figure 7-1 Late Stage Cancer Compounds in Development for Major Indications

CORPORATE PROFILES

Figure 8-1 Late stage Cancer Therapies in Development for Leading Companies